Clinical Trials Logo

Clinical Trial Summary

The purpose of this investigation is to evaluate the safety, tolerability, preliminary and long-term effectiveness of utilizing the ReCell Autologous Cell Harvesting Device (ReCell) combined with widened split-thickness skin graft (STSG) mesh onto the dermal regenerate INTEGRA™ Meshed Bilayer Wound Matrix (MBWM) for healing of full-thickness wounds.


Clinical Trial Description

The goal of the study described herein is to determine the safety, tolerability, preliminary and long-term effectiveness of the use of the Recell device over a widened STSG mesh. It is hypothesized the ReCell cell suspension, in combination with INTEGRA™ MBWM, will improve upon the current standard of care. The potential for ReCell's promotion of healing in the interstices of the STSG mesh may close gaps that are potential points of failure during subsequent rehabilitation and return to physical activity. Within the current study, each participant will serve as his/her own control, allowing for comparison of ReCell treated (experimental) and non-ReCell treated (control) regions of the grafted wound. In the proposed study, each patient will serve as his/her own control. Due to the nature of the study, only patients whose wounds have been previously successfully treated with INTEGRA™ MBWM as part of their standard of care will qualify for participation.

Therefore, as part of enrollment eligibility criteria for this study, the identified study wound will first be treated with INTEGRA™ MBWM. The wound will then be allowed to heal for approximately two to four weeks, at which time a viable granulation layer will have developed thus allowing for next stage STSG grafting. The timing of the STSG application will be determined by clinician judgment based on the state of the granulation process, which varies between patients, but typically takes 2 to 4 weeks.

Approximately two to four weeks after INTEGRA™ MBWM treatment, the studied wound will be divided into a ReCell-treated area (over 1:5 meshed STSG) and a control area treated with 1:1.5 meshed STSG (no ReCell). In all cases, the ReCell region may be up to 320cm2 in size; the upper limit of application area for one ReCell kit, with a similarly sized control region. If the wound is larger than the combined ReCell and control regions (over 640cm2), the areas outside the study regions will be designated as non-study areas and treated according to standard of care. The same primary and secondary dressings will be used on ReCell-treated areas, control areas and donor sites. Once the study and control wounds are determined to have healed, standard local clinical practice will be followed.

Within-subject comparisons of the ReCell region and control region, in order to evaluate improvements associated with use of ReCell, a battery of measurements and evaluations will be made. These measurements are divided into three categories: safety and tolerability, preliminary effectiveness (acute healing process) and long-term effectiveness.

The safety of research participants is foremost. Therefore, efforts will be made to control risks to participants throughout the duration of their study participation. Wound healing time, donor site morbidity and histology will be assessed during an acute 6 week phase, with follow-up visits at Weeks 1, 2, 3, 4 and 6 post-treatment.

Subjects will continue in the study for long-term follow-up with clinic visits at Week 12 and 24 post-treatment. Healing of treated wound sites (A region and B region) and donor sites (STSG 1:5, STSG 1:1.5 and ReCell) will be assessed at each visit. Treated wounds will be considered healed when 95% or greater of the study area has re-epithelialized by Week 6 post-treatment. Donor sites will be considered healed when ≥95% of the donor site has re-epithelialized by Week 4 post-treatment. Aesthetic and functional outcomes of the treated areas will be assessed and documented. Subject satisfaction will also be assessed and documented at these two time points. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02469168
Study type Interventional
Source University of Pittsburgh
Contact
Status Terminated
Phase N/A
Start date December 2014
Completion date December 2017

See also
  Status Clinical Trial Phase
Completed NCT02655354 - A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity N/A
Active, not recruiting NCT04534959 - Strategy to Avoid Excessive Oxygen for Critically Ill Trauma Patients Phase 3
Not yet recruiting NCT04387305 - Traumatic Injury Clinical Trial Evaluating Tranexamic Acid in Children: An Efficacy Study Phase 3
Recruiting NCT05411484 - Investigation of Laser Assisted Drug Delivery of NanoDOX® Phase 2
Completed NCT02884999 - Management of Bleeding and Coagulopathy in Trauma and Compliance to European Trauma Guidelines N/A
Recruiting NCT03400345 - Human Upper Extremity Allotransplantation: F/U Protocol
Recruiting NCT04460872 - Locomotor Training With Testosterone to Promote Bone and Muscle Health After Spinal Cord Injury Phase 2
Completed NCT03764930 - Attention to Retinoblastoma Diagnosed in the Trauma Setting
Completed NCT04753723 - The Use of a Platform Wound Device for Reducing Infection Phase 4
Completed NCT03805646 - Mobile Phone-administered Triage Tool to Followup on Discharged Trauma Patients N/A
Not yet recruiting NCT03191279 - First Aid by Laypersons - Effect on Mortality and Length of Stay N/A
Recruiting NCT06374225 - Strategy to Avoid Excessive Oxygen Using an Autonomous Oxygen Titration Intervention N/A
Completed NCT01594385 - Seprafilm in Open Abdomens: a Study of Wound and Adhesion Characteristics in Trauma Damage Control Patients N/A
Active, not recruiting NCT04534972 - Strategy to Avoid Excessive Oxygen in Major Burn Patients Phase 3